CoChat

An Asian monogenic diabetes registry: prevalence, long-term renal trajectory and development of a diagnostic algorithm for selection of candidates for genetic testing

Tan, Clara Si Hua, Kee, Kai Xiang, Zheng, Huili, Chan, Lovynn Wan Ting, Song, Yuzhen, Kon, Winston Yin Chian, Chee, Ying Jie, Lian, Joyce Xia, Vasanwala, Rashida Farhad, Yap, Fabian Kok Peng, Loh, Wann Jia, Subramaniam, Tavintharan, Sum, Chee Fang, Lim, Su Chi · 2025 · Singapore Medical Journal
Cited by 4

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Introduction: Through the National Healthcare Group–Khoo Teck Puat Hospital Monogenic Diabetes Registry, we aimed to determine the prevalence and spectrum of maturity-onset diabetes of the young (MODY), describe the long-term renal trajectory of major MODY subtypes, and develop a diagnostic algorithm based on a combination of clinical parameters and biomarkers to refine selection of candidates for genetic testing. Methods: A total of 373 study participants attending secondary care diabetes centres in Singapore were referred for genetic testing. Key inclusion criteria for genetic testing included onset age ≤35 years, body mass index <32.5 kg/m 2 and absence of glutamic acid decarboxylase autoantibody. Results: Analysis of 16 genes and one mitochondrial variant led to a molecular diagnosis in 49 participants, with pathogenic variants present mostly in HNF1A (29%), HNF4A (23%) and GCK (15%). Long-term renal trajectory data observed between these major MODY subtypes were not significantly different, but some key observations were typical for each subgroup. For instance, patients with HNF4A -MODY were predisposed to the risk of microvascular complications (i.e., diabetic kidney disease), while patients with GCK -MODY had mild and non-progressive hyperglycaemia. A structured diagnostic algorithm, including readily available biomarkers such as high-sensitive C-reactive protein (hs-CRP) and high-density lipoprotein-cholesterol (HDL-c), provided 71% diagnostic accuracy, achieving a negative predictive value of 0.94 and a sensitivity of 0.68. Conclusion: The prevalence of MODY (13%) is non-trivial among young-onset diabetes referred for genetic testing based on clinical classifiers suggestive of MODY. Current clinical assessment tools may include hs-CRP and HDL-c to refine selection of candidates for genetic testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/singaporemedj.smj-2024-012

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 37

  1. Tattersall, 1974, Mild familial diabetes with dominant inheritance, Q J Med, 43, 339
  2. Bosselaar, 2002, High sensitivity to sulphonylurea treatment in 2 patients with maturity-onset diabetes of the young type 3, Ned Tijdschr Geneeskd, 146, 726
  3. Shepherd, 2018, A UK nationwide prospective study of treatment change in MODY: Genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin, Diabetologia, 61, 2520, 10.1007/s00125-018-4728-6 · DOI · Paper page
  4. Broome, 2020, Novel use of GLP-1 receptor agonist therapy in HNF4A-MODY, Diabetes Care, 43, e65, 10.2337/dc20-0012 · DOI
  5. Bowman, 2018, Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: An international cohort study, Lancet Diabetes Endocrinol, 6, 637, 10.1016/S2213-8587(18)30106-2 · DOI · Paper page
  6. Iafusco, 2011, No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes, Diabetologia, 54, 2736, 10.1007/s00125-011-2273-7 · DOI
  7. Steele, 2013, Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: Observation case control studies, PLoS One, 148, e65326, 10.1371/journal.pone.0065326 · DOI · Paper page
  8. Steele, 2014, Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia, JAMA, 311, 279, 10.1001/jama.2013.283980 · DOI · Paper page
  9. Timsit, 2021, Pregnancy in women with monogenic diabetes due to pathogenic variants of the glucokinase gene: Lessons and challenges, Front Endocrinol, 12, 802423, 10.3389/fendo.2021.802423 · DOI
  10. Shields, 2008, Mutations in the glucokinase gene of the fetus result in reduced placental weight, Diabetes Care, 31, 753, 10.2337/dc07-1750 · doi:10.2337/dc07-1750
  11. Dubois-Laforgue, 2017, Diabetes, associated clinical spectrum, long-term prognosis, and genotype/phenotype correlations in 201 adult patients with hepatocyte nuclear factor 1B (HNF1B) molecular defects, Diabetes Care, 40, 1436, 10.2337/dc16-2462 · DOI · Paper page
  12. Johansson, 2011, Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): A protein misfolding disease, J Biol Chem, 286, 34593, 10.1074/jbc.M111.222679 · DOI
  13. Mohan, 2019, Comprehensive genomic analysis identifies pathogenic variants in maturity-onset diabetes of the young (MODY) patients in South India, BMC Med Genet, 19, 22, 10.1186/s12881-018-0528-6 · DOI
  14. Chapla, 2015, Maturity onset diabetes of the young in India – A distinctive mutation pattern identified through targeted next-generation sequencing, Clin Endocrinol, 82, 533, 10.1111/cen.12541 · DOI
  15. Shields, 2012, The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes, Diabetologia, 55, 1265, 10.1007/s00125-011-2418-8 · DOI · Paper page
  16. Misra, 2016, South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people, Diabetologia, 59, 2262, 10.1007/s00125-016-4056-7 · DOI
  17. Chauhan, 2012, TG/HDL ratio: A marker for insulin resistance and atherosclerosis in prediabetics or not?, J Family Med Prim Care, 10, 3700, 10.4103/jfmpc.jfmpc_165_21 · DOI
  18. Epstein, 2013, Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes, Diabetes Care, 36, 2280, 10.2337/dc12-1693 · DOI · Paper page
  19. Whelton, 2018, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines, J Am Coll Cardiol, 71, e127, 10.1016/j.jacc.2017.11.006 · DOI · Paper page
  20. Ang, 2020, Clinical experience from a regional monogenic diabetes referral centre in Singapore, Diabetes Res Clin Pract, 168, 108390, 10.1016/j.diabres.2020.108390 · DOI
  21. Ang, 2016, A preliminary study to evaluate the strategy of combining clinical criteria and next generation sequencing (NGS) for the identification of monogenic diabetes among multi-ethnic Asians, Diabetes Res Clin Pract, 119, 13, 10.1016/j.diabres.2016.06.008 · DOI
  22. Tan, 2022, MODY5 Hepatocyte nuclear factor 1B (HNF1B)-associated nephropathy: Experience from a regional monogenic diabetes referral centre in Singapore, J Investig Med High Impact Case Rep, 10, 1
  23. Vigouroux, 2018, Lipodystrophic syndromes due to LMNA muations: Recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives, Nucleus, 9, 235, 10.1080/19491034.2018.1456217 · DOI
  24. Colclough, 2022, Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of maturity-onset diabetes of the young, Diabetes, 71, 530, 10.2337/db21-0517 · DOI
  25. Owen, 2010, Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations, Diabetes Care, 33, 1919, 10.2337/dc10-0288 · DOI · Paper page
  26. McDonald, 2012, Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and type 2 diabetes, Clin Chim Acta, 413, 927, 10.1016/j.cca.2012.02.005 · DOI
  27. Fendler, 2011, HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults, Clin Endocrinol, 75, 321, 10.1111/j.1365-2265.2011.04052.x · doi:10.1111/j.1365-2265.2011.04052.x
  28. Tfayli, 2009, Phenotypic type 2 diabetes in obese youth: Insulin sensitivity and secretion in islet cell antibody-negative versus – positive patients, Diabetes, 58, 738, 10.2337/db08-1372 · DOI · Paper page
  29. Besser, 2011, Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 4-(alpha) maturity-onset diabetes of the young from long-duration type 1 diabetes, Diabetes Care, 34, 286, 10.2337/dc10-1293 · DOI · Paper page
  30. Agladioglu, 2015, Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: A single-center experience, Hormone Res Paediatr, 84, 54, 10.1159/000375410 · DOI
  31. Besser, 2013, Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes, Pediatr Diabetes, 14, 181
  32. Nauck, 2009, Incretin-based therapies: Viewpoints on the way to consensus, Diabetes Care, 32, S223, 10.2337/dc09-S315 · DOI · Paper page
  33. Hu, 2021, Association between plasma uric acid and insulin resistance in type 2 diabetes: A Mendelian randomization analysis, Diabetes Res Clin Pract, 171, 108542, 10.1016/j.diabres.2020.108542 · DOI
  34. Xiong, 2019, Effects of uric acid on diabetes mellitus and its chronic complications, Int J Endocrinol, 2019, 9691345, 10.1155/2019/9691345 · DOI
  35. DeFronzo, 1979, Glucose clamp technique: A method for quantifying insulin secretion and resistance, Am J Physiol, 237, E214
  36. Bergman, 1985, Assessment of insulin sensitivity in vivo, Endocr Rev, 6, 45, 10.1210/edrv-6-1-45 · DOI · Paper page
  37. McDonald, 2011, Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes, Diabetic Med, 28, 1028, 10.1111/j.1464-5491.2011.03287.x · DOI · Paper page

Cited by

See all 4

Metadata

Authors
Tan, C. S. H., Kee, K. X., Zheng, H., Chan, L. W. T., Song, Y., Kon, W. Y. C., Chee, Y. J., Lian, J. X., Vasanwala, R. F., Yap, F. K. P., Loh, W. J., Subramaniam, T., Sum, C. F., & Lim, S. C.
Affiliations
  • Clinical Research Unit, Khoo Teck Puat Hospital, Singapore
  • Department of Endocrinology, Tan Tock Seng Hospital, Singapore
  • Department of Endocrinology, KKH Women’s and Children’s Hospital, Singapore
  • Department of Endocrinology, Changi General Hospital, Singapore
  • Diabetes Centre, Admiralty Medical Centre, Singapore
Venue
Singapore Medical Journal
Published
2025-02-18
ISSN
  • 0037-5675
  • 2737-5935
Cited by
4
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Asian monogenic diabetes registry: prevalence, long-term renal trajectory and development of a diagnostic algorithm for selection of candidates for genetic testing. https://app.cochat.ai/papers/10.4103/singaporemedj.smj-2024-012
The paper
Tan, C. S. H., Kee, K. X., Zheng, H., Chan, L. W. T., Song, Y., Kon, W. Y. C., Chee, Y. J., Lian, J. X., Vasanwala, R. F., Yap, F. K. P., Loh, W. J., Subramaniam, T., Sum, C. F., & Lim, S. C. (2025). An Asian monogenic diabetes registry: prevalence, long-term renal trajectory and development of a diagnostic algorithm for selection of candidates for genetic testing. Singapore Medical Journal. https://doi.org/10.4103/singaporemedj.smj-2024-012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.